Cancer Immunotherapy 101
Thursday, August 18, 2016 • 8:00 a.m. – noon
|
Specifically designed for clinical oncologists, registered nurses, pharmacists and the entire medical team involved in treating cancer patients with immunotherapy, this introductory, CME- and CE-certified program provided an overview of basic immunology principles and the mechanisms and clinical applications of immunotherapy for melanoma, lung cancer and genitourinary cancers.
Presented by leading authorities in tumor immunology and cancer immunotherapy, this program facilitated understanding of 1) the basic principles of tumor immunology and immunotherapy, 2) the clinical indications for immunotherapy and the appropriate selection and management of patients, 3) emerging concepts and agents in the cancer immunotherapy field, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.
Attendees were also able to take advantage of the opportunity for professional networking that may promote collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.
The target audience for this program was patient care providers and others who wish to learn the basic principles of tumor immunology and immunotherapy, and to improve their ability to integrate immunotherapy into state-of-the art clinical management for their patients. This intended audience includes clinical oncologists, registered nurses, nurse practitioners, pharmacists, allied health professionals, other patient care providers, students and patient advocates.
Attendees received pre-program material located here. These slides provided an overview of immunology principles that was covered during the program and introduced participants to the immunological mechanisms underlying immunotherapy approaches. The program on August 18 began by offering attendees the opportunity to ask questions about these slides, followed by a presentation about this information, especially as it pertains to immunotherapy.
The objectives for this program were for participants to be able, upon completion,to:
Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center
Joseph W. Fay, MD – Baylor University Medical Center
Hideho Okada, MD, PhD – University of California San Francisco
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC
Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
Alexander Spira, MD, PhD – Virginia Cancer Specialists
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Center
Eleni Yeatras, RPh, BCOP – Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer
In collaboration with Memorial Sloan Kettering Cancer Center and Rutgers Cancer Institute of New Jersey
The Advances in Cancer Immunotherapy™ series is supported in part by independent medical educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck & Co., Inc.
Event staff is always glad to assist attendees with any special needs (i.e., physical, dietary, etc.). Attendees with special needs are requested contact SITC prior to live events at (414) 271-2456.
View a list of upcoming Advances in Cancer ImmunotherapyTM 2016 regional programs.